Targeted therapy of cancer: New prospects for antibodies and immunoconjugates

被引:176
作者
Sharkey, Robert M. [1 ]
Goldenberg, David M. [1 ]
机构
[1] Ctr Mol Med & Immunol, Garden State Canc Ctr, Belleville, NJ 07109 USA
关键词
D O I
10.3322/canjclin.56.4.226
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunotherapy of cancer has been explored for over a century, but it is only in the last decade that various antibody-based products have been introduced into the management of patients with diverse cancers. At present, this is one of the most active areas of clinical research, with eight therapeutic products already approved in oncology. Antibodies against tumor-associated markers have been a part of medical practice in immunohistology and in vitro immunoassays for several decades, have even been used as radioconjugates in diagnostic imaging, and are now becoming increasingly recognized as important biological agents for the detection and treatment of cancer. Molecular engineering has improved the prospects for such antibody-based therapeutics, resulting in different constructs and humanized/human antibodies that can be administered frequently. Consequently, a renewed interest in the development of antibodies conjugated with radionuclides, drugs, and toxins has emerged. We review how antibodies and immunoconjugates have influenced cancer detection and therapy, and also describe promising new developments and challenges for broader applications.
引用
收藏
页码:226 / 243
页数:18
相关论文
共 196 条
[61]   Combined 90yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft [J].
Gold, DV ;
Modrak, DE ;
Schutsky, K ;
Cardillo, TM .
INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (04) :618-626
[62]  
Gold DV, 2003, CLIN CANCER RES, V9, p3929S
[63]  
Goldenberg DM, 1997, CANCER-AM CANCER SOC, V80, P2431, DOI 10.1002/(SICI)1097-0142(19971215)80:12+<2431::AID-CNCR15>3.3.CO
[64]  
2-L
[65]   Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy [J].
Goldenberg, DM ;
Sharkey, RM ;
Paganelli, G ;
Barbet, J ;
Chatal, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (05) :823-834
[66]   USE OF RADIOLABELED ANTIBODIES TO CARCINOEMBRYONIC ANTIGEN FOR DETECTION AND LOCALIZATION OF DIVERSE CANCERS BY EXTERNAL PHOTOSCANNING [J].
GOLDENBERG, DM ;
DELAND, F ;
KIM, E ;
BENNETT, S ;
PRIMUS, FJ ;
VANNAGELL, JR ;
ESTES, N ;
DESIMONE, P ;
RAYBURN, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1978, 298 (25) :1384-1388
[67]   TARGETING, DOSIMETRY, AND RADIOIMMUNOTHERAPY OF B-CELL LYMPHOMAS WITH IODINE-131-LABELED LL2 MONOCLONAL-ANTIBODY [J].
GOLDENBERG, DM ;
HOROWITZ, JA ;
SHARKEY, RM ;
HALL, TC ;
MURTHY, S ;
GOLDENBERG, H ;
LEE, RE ;
STEIN, R ;
SIEGEL, JA ;
IZON, DO ;
BURGER, K ;
SWAYNE, LC ;
BELISLE, E ;
HANSEN, HJ ;
PINSKY, CM .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (04) :548-564
[68]   PILOT TRIAL OF MURINE MONOCLONAL-ANTIBODIES IN PATIENTS WITH ADVANCED MELANOMA [J].
GOODMAN, GE ;
BEAUMIER, P ;
HELLSTROM, I ;
FERNYHOUGH, B ;
HELLSTROM, KE .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (03) :340-352
[69]   High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis [J].
Gopal, AK ;
Gooley, TA ;
Maloney, DG ;
Petersdorf, SH ;
Eary, JF ;
Rajendran, JG ;
Bush, SA ;
Durack, LD ;
Golden, J ;
Martin, PJ ;
Matthews, DC ;
Appelbaum, FR ;
Bernstein, ID ;
Press, OW .
BLOOD, 2003, 102 (07) :2351-2357
[70]   Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma:: long-term follow-up of a phase 1/2 study [J].
Gordon, LI ;
Molina, A ;
Witzig, T ;
Emmanouilides, C ;
Raubtischek, A ;
Darif, M ;
Schilder, RJ ;
Wiseman, G ;
White, CA .
BLOOD, 2004, 103 (12) :4429-4431